Completed PHASE2 INTERVENTIONAL 2-arm NCT03533478

Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema

Efficacy of Nutritional Supplements Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema. Clinical Trial Phase II.

Sponsor: Catalysis SL

Conditions Diabetic Macular Edema

Interventions Oral treatment Alzer y Diamel Placebo

Updated 5 times since 2018 Last updated: May 21, 2019 Started: Mar 1, 2015 Primary completion: Dec 1, 2018 Completion: Dec 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diabetic Macular Edema and is currently completed. Catalysis SL leads this study, which shows 5 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Jun 2019 [monthly]

Active Not Recruiting PHASE2

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Catalysis SL

Data source: Catalysis SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vedado, Cuba